SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-17-014271
Filing Date
2017-08-09
Accepted
2017-08-09 15:47:55
Documents
74
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20170630_10q.htm 10-Q 1385544
2 EXHIBIT 31.1 ex31-1.htm EX-31.1 10412
3 EXHIBIT 31.2 ex31-2.htm EX-31.2 10256
4 EXHIBIT 32.1 ex32-1.htm EX-32.1 5278
5 EXHIBIT 32.2 ex32-2.htm EX-32.2 5162
  Complete submission text file 0001437749-17-014271.txt   7695407

Data Files

Seq Description Document Type Size
6 EXHIBIT 101.INS navb-20170630.xml EX-101.INS 1792289
7 EXHIBIT 101.SCH navb-20170630.xsd EX-101.SCH 63124
8 EXHIBIT 101.CAL navb-20170630_cal.xml EX-101.CAL 63746
9 EXHIBIT 101.DEF navb-20170630_def.xml EX-101.DEF 522674
10 EXHIBIT 101.LAB navb-20170630_lab.xml EX-101.LAB 405928
11 EXHIBIT 101.PRE navb-20170630_pre.xml EX-101.PRE 542103
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 171017740
SIC: 2835 In Vitro & In Vivo Diagnostic Substances